Physician profile
Amy Patton
NPI 1033891726
$597.98
in general payments reported to CMS, 2019-2025
11 companies · $51.65 in 2025
The $51.65 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $546 · 2025: $51.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $166.31 | 2024 | |
| Janssen Biotech, INC. | $133.86 | 2024 | Tremfya, Simponi Aria |
| Amgen INC. | $109.37 | 2024 | Enbrel, Otezla, Tavneos |
| Solventum Corporation | $34.48 | 2025 | Activ.A.C. |
| Novartis Pharmaceuticals Corporation | $33.49 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.77 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $24.35 | 2024 | |
| Ucb, INC. | $18.82 | 2024 | Cimzia |
| Pfizer INC. | $18.44 | 2024 | |
| Smith+Nephew, INC. | $17.17 | 2025 | Collagenase Santyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.92 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.